Association between anemia arising during therapy and outcomes of chemoradiation for limited small-cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 2, 2006, Pages 146-151

  Laurie, Scott A ^a   Jeyabalan, Neera ^b   Nicholas, Garth ^a   MacRae, Robert ^a   Dahrouge, Simone ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anemia; Combined modality therapy; Predictive; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ERYTHROPOIETIN; ETOPOSIDE; PLATINUM; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; DEATH; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFORMATION PROCESSING; LUNG SMALL CELL CANCER; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SUPRACLAVICULAR ADENOPATHY; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; CANADA; DISEASE COURSE; DRUG COMBINATION; FOLLOW UP; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONTARIO; PREVALENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34247884344     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200602000-00008     Document Type: Article

References (28)

1. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.
2. Obermair A, Cheuk R, Horwood K, et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma. Cancer 2001;92:903-908.
3. MacRae R, Shyr Y, Johnson DH, Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 2002;64:37-40.
4. Laurie SA, Logan D, Markman BR, et al. Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer 2004;43:223-240.
5. National Comprehensive Cancer Network guidelines: Small cell lung cancer. Cancer Control 2001;8 (Suppl 2):32-43.
6. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993;11:336-344.
7. Pignon J-P, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624.
8. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-895.
9. Bremnes RM, Sundstrom S, Aasebo U, et al. The value of prognostic factors in small cell lung cancer: Results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003;39:303-313.
10. Ash R, Videtic G, Rodrigues G, et al. The impact of hemoglobin levels on outcome in limited stage small cell lung cancer. Lung Cancer 2006;49(Suppl 2):S316.
11. Laurie S, Ding K, Whitehead M, et al. Impact of anemia on outcomes of therapy in limited small cell lung cancer (L-SCLC): An analysis of studies performed by the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG). Lung Cancer 2006;49(Suppl 2):S323.
12. Auperin A, Arriagada R, Pignon J-P, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341:476-484.
13. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.
14. Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-1075.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Cox DR. Regression models and life table. J R Stat Soc B 1972;34:181-220.
17. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-4672.
18. Grau C, Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor using a local tumor control assay. Radiother Oncol 1988;13:301-309.
19. Fried DB, Morris DE, Hensing TA, et al. Timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer: A meta-analysis. Lung Cancer 2003;41(Suppl 2):S23.
20. Bush RS, Jenkin RDT, Allt WEC, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978;37:302-306.
21. Overgaard J, Hansen HS, Overgaard M, et al. A randomized doubleblind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-146.
22. Thatcher N, de Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80:396-402.
23. Quirt I, Robeson CY, Lau M, et al. Epoetin alpha therapy increases hemoglobin levels and improves quality of life in patients with cancerrelated anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-4134.
24. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
25. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
26. Machtay M, Pajak T, Suntharalingam M, et al. Definitive radiotherapy plus or minus erythropoietin for squamous cell carcinoma of the head and neck: Preliminary report of RTOG 99-03 (Abstract). Int J Radiat Oncol Biol Phys 2004;60(Suppl 1):S132.
27. Goss G, Feld R, Bezjak A, et al. Impact of maintaining hemoglobin with epoetin alfa on time to progression (TTP), overall survival (OS), quality of life (QOL) and transfusion reduction in limited disease SCLC patients (Abstract). Lung Cancer 2006;49(Suppl 2):S53.
28. Fyles AW, Milosevic M, Pintilie M, et al. Anemia, hypoxia and transfusion in patients with cervix cancer: A review. Radiother Oncol 2000;57:13-19.